MC2 Therapeutics to Current at Upcoming Conferences
Copenhagen, February twenty sixth, 2024 – MC2 Therapeutics, a business stage biotech firm targeted on creating novel therapy paradigms inside immunology and irritation, declares at present that its management will attend and current on the following business conferences:
Any webcasts will likely be accessible on MC2’s web site following the shows. Please contact us if you want to rearrange a gathering.
About MC2 Therapeutics
MC2 Therapeutics is a business stage biotech firm targeted on creating novel therapy paradigms inside immunology and irritation. Its pioneering method in immunology is anchored in a deep understanding of pores and skin biology, scientific experience and cross-silo pondering.
Its pipeline consists of two first-in-class drug candidates each in Section 2 scientific improvement, with novel modes of motion and blockbuster potential in a number of indications (“I&I pipeline in a product”):
-
MC2-32: an oral HSP90 inhibitor with distinctive tissue particular focusing on and a brand new MOA that modulates a number of pro-inflammatory pathways and related immune responses.
-
MC2-25: an iso-cyanate scavenger addressing carbamylation of proteins and amino acids within the pores and skin by iso-cyanate, a dissociation product of urea.
For extra data on MC2 Therapeutics, please go to www.mc2therapeutics.com.
Contacts:
Lonni Goltermann, +45 2018 1111, [email protected]
Media: ICR Consilium
Amber Fennell, +44 20 3709 5700, [email protected]